PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Oeckl, P.* ; Anderl-Straub, S.* ; Danek, A.* ; Diehl-Schmid, J.* ; Fassbender, K.* ; Fliessbach, K.* ; Halbgebauer, S.* ; Huppertz, H.J.* ; Jahn, H.* ; Kassubek, J.* ; Kornhuber, J.* ; Landwehrmeyer, B.* ; Lauer, M.* ; Prudlo, J.* ; Schneider, A.* ; Schroeter, M.L.* ; Steinacker, P.* ; Volk, A.E.* ; Wagner, M. ; Winkelmann, J. ; Wiltfang, J.* ; Ludolph, A.C.* ; Otto, M.*

Relationship of serum beta-synuclein with blood biomarkers and brain atrophy.

Alzheimers Dement. 19, 1358-1371 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Background: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD). Methods: We provide a detailed comparison of serum beta-synuclein immunoprecipitation – mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores. Results: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy. Discussion: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations. Highlights: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL).
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
16.655
4.118
6
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Alzheimer's Disease ; Beta-synuclein ; Blood Biomarker ; Brain Atrophy ; Dementia ; Frontotemporal Lobar Degeneration ; Ftld ; Nfl ; P-tau181 ; Synaptic Degeneration; Alzheimers-disease; Cerebrospinal-fluid; Diagnosis; Criteria; Guidelines; Pathology; Dementia
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1552-5260
e-ISSN 1552-5279
Zeitschrift Alzheimer's & Dementia
Quellenangaben Band: 19, Heft: 4, Seiten: 1358-1371 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort New York, NY [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Neurogenomics (ING)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-503200-001
Förderungen Deutsche Forschungsgemeinschaft
DOI 10.1002/alz.12790
WOS ID 000855791900001
Scopus ID 85138439376
PubMed ID 36129098
Erfassungsdatum 2022-10-13
[➜Korrektur melden]